These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2105248)

  • 1. Effects of gonadotropin-releasing hormone agonist and clomiphene citrate on estrogen/progesterone-induced hyperprolactinemia in monkeys.
    Groff TR; Olive DL; Riehl RM; Schenken RS
    Fertil Steril; 1990 Feb; 53(2):346-50. PubMed ID: 2105248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gonadotropin-releasing hormone antagonists attenuate estrogen/progesterone-induced hyperprolactinemia in monkeys.
    Olive DL; Sabella V; Riehl RM; Schenken RS; Moreno A
    Fertil Steril; 1989 Jun; 51(6):1040-5. PubMed ID: 2656304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clomiphene citrate attenuates hyperprolactinemia associated with ovarian hyperstimulation in the primate menstrual cycle.
    Simon JA; Gianfortoni JG; Hodgen GD
    J Clin Endocrinol Metab; 1988 Apr; 66(4):811-4. PubMed ID: 3346359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of clomiphene citrate and leuprolide acetate on luteal-phase hyperprolactinemia during ovarian stimulation with menopausal gonadotropins.
    Kaplan CR; Koong MK; Olive DL; Riehl RM; Burns WN; Groff TR; Schenken RS
    J In Vitro Fert Embryo Transf; 1991 Dec; 8(6):308-13. PubMed ID: 1770270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gonadotropin-releasing hormone antagonist versus agonist administration in women undergoing controlled ovarian hyperstimulation: cycle performance and in vitro steroidogenesis of granulosa-lutein cells.
    Minaretzis D; Alper MM; Oskowitz SP; Lobel SM; Mortola JF; Pavlou SN
    Am J Obstet Gynecol; 1995 May; 172(5):1518-25. PubMed ID: 7755066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human menopausal gonadotropin/human chorionic gonadotropin-induced ovarian hyperstimulation with transient hyperprolactinemia: steroidogenesis enhanced during bromocriptine therapy in monkeys.
    Collins RL; Williams RF; Hodgen GD
    J Clin Endocrinol Metab; 1984 Oct; 59(4):727-33. PubMed ID: 6434577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperprolactinemia induced by an estrogen-progesterone synergy: quantitative and temporal effects of estrogen priming in monkeys.
    Williams RF; Gianfortoni JG; Hodgen GD
    J Clin Endocrinol Metab; 1985 Jan; 60(1):126-32. PubMed ID: 3964786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of luteal metoclopramide-induced hyperprolactinemia on pituitary and luteal responsiveness to gonadotropin-releasing hormone.
    Caruso A; Lanzone A; Fulghesu AM; Apa R; Guida C; Mancuso S
    Horm Res; 1989; 31(4):169-74. PubMed ID: 2507435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clomiphene citrate affects cervical mucus and endometrial morphology independently of the changes in plasma hormonal levels induced by multiple follicular recruitment.
    Massai MR; de Ziegler D; Lesobre V; Bergeron C; Frydman R; Bouchard P
    Fertil Steril; 1993 Jun; 59(6):1179-86. PubMed ID: 8495762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pituitary function is altered during the same cycle in women with polycystic ovary syndrome treated with continuous or cyclic oral contraceptives or a gonadotropin-releasing hormone agonist.
    Ruchhoft EA; Elkind-Hirsch KE; Malinak R
    Fertil Steril; 1996 Jul; 66(1):54-60. PubMed ID: 8752611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitory effects of a gonadotropin-releasing hormone agonist on the luteal synthesis of progesterone, estradiol receptors, and prolactin surges during early pregnancy.
    Sridaran R; Ghose M; Mahesh VB
    Endocrinology; 1988 Oct; 123(4):1740-6. PubMed ID: 3046924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of gonadotrophin-releasing hormone agonists administered as desensitizing or flare protocols on hormonal function in the luteal phase of hyperstimulated cycles.
    Norman RJ; Warnes GM; Wang X; Kirby CA; Matthews CD
    Hum Reprod; 1991 Feb; 6(2):206-13. PubMed ID: 1905309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolactin suppresses GnRH but not TSH secretion.
    Page-Wilson G; Smith PC; Welt CK
    Horm Res; 2006; 65(1):31-8. PubMed ID: 16357488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of clomiphene citrate on follicular and luteal phase luteinizing hormone concentrations in in vitro fertilization cycles stimulated with gonadotropins and gonadotropin-releasing hormone antagonist.
    Tavaniotou A; Albano C; Smitz J; Devroey P
    Fertil Steril; 2002 Apr; 77(4):733-7. PubMed ID: 11937125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of clomiphene citrate during ovarian stimulation on the luteal phase after GnRH agonist trigger.
    Derksen L; Tournaye H; Stoop D; Van Vaerenbergh I; Bourgain C; Polyzos NP; Haentjens P; Blockeel C
    Reprod Biomed Online; 2014 Mar; 28(3):359-68. PubMed ID: 24456700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transient hyperprolactinemia during cycle stimulation and its influence on oocyte retrieval and fertilization rates.
    Hummel WP; Clark MR; Talbert LM
    Fertil Steril; 1990 Apr; 53(4):677-81. PubMed ID: 2108058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gonadotropin-releasing hormone agonist-induced ovarian hyperstimulation: low-dose side effects in women and monkeys.
    Navot D; Rosenwaks Z; Anderson F; Hodgen GD
    Fertil Steril; 1991 Jun; 55(6):1069-75. PubMed ID: 1828042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of mifepristone (RU486) on the pituitary response to gonadotrophin releasing hormone in women.
    Kazem R; Messinis LE; Fowler P; Groome NP; Knight PG; Templeton AA
    Hum Reprod; 1996 Dec; 11(12):2585-90. PubMed ID: 9021355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen induces premature luteal regression in rhesus monkeys during spontaneous menstrual cycles, but not in cycles driven by exogenous gonadotropin-releasing hormone.
    Hutchison JS; Kubik CJ; Nelson PB; Zeleznik AJ
    Endocrinology; 1987 Aug; 121(2):466-74. PubMed ID: 3297646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovulation inhibition by administration of weekly gonadotropin-releasing hormone antagonist.
    Kenigsberg D; Hodgen GD
    J Clin Endocrinol Metab; 1986 Apr; 62(4):734-8. PubMed ID: 3081571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.